Scarica l'app Stockscreener
1.32
5.60%
0.07
Dopo l'orario di chiusura:
1.34
0.02
+1.52%
Precedente Chiudi:
$1.25
Aprire:
$1.24
Volume 24 ore:
249.05K
Relative Volume:
0.24
Capitalizzazione di mercato:
$17.44M
Reddito:
-
Utile/perdita netta:
$-7.51M
Rapporto P/E:
-1.00
EPS:
-1.32
Flusso di cassa netto:
$-8.02M
1 W Prestazione:
-7.69%
1M Prestazione:
+9.09%
6M Prestazione:
-7.04%
1 anno Prestazione:
+60.54%
Intervallo 1D:
$1.2333
$1.35
Intervallo di 1 settimana:
$1.2333
$1.44
Portata 52W:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Nome
Hoth Therapeutics Inc
Settore
Industria
Telefono
(646)756-2997
Indirizzo
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Confronta HOTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.32 | 18.89M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-10-15 | Iniziato | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Borsa (HOTH) Ultime notizie
Is Hoth Therapeutics Inc. a good long term investmentUnprecedented growth rates - Autocar Professional
What analysts say about Hoth Therapeutics Inc. stockFree Stock Selection - Autocar Professional
What drives Hoth Therapeutics Inc. stock pricePowerful profit generation - PrintWeekIndia
Hoth Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - PrintWeekIndia
How Hoth Therapeutics Inc. stock performs during market volatilitySwing Trade Signals - Newser
Why Hoth Therapeutics Inc. stock attracts strong analyst attention10x Return With Managed Risk - Newser
What makes Hoth Therapeutics Inc. stock price move sharplyDaily Volume Leaders - Newser
Hoth Therapeutics (NASDAQ:HOTH) Upgraded by Wall Street Zen to Hold Rating - Defense World
Silo Pharma and Hoth Therapeutics plan joint venture for obesity treatment - Investing.com India
Hoth Therapeutics Advances HT-001 for Cancer Treatment - TipRanks
HT-001's Breakthrough in Oncology Supportive Care: A Game-Changer for Hoth Therapeutics? - AInvest
Hoth Therapeutics stock rises after positive Phase 2a trial results - Investing.com India
Leading Cancer Experts Reveal Phase 2 Data for Revolutionary Skin Toxicity Treatment HT-001 - Stock Titan
Hoth Therapeutics Regains Nasdaq Compliance on June 18 - TipRanks
Hoth Therapeutics reports positive preclinical safety data for HT-KIT By Investing.com - Investing.com South Africa
Hoth Therapeutics Regains Nasdaq Compliance - MarketScreener
Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid - Investing.com
Hoth Therapeutics Just Cleared Critical Nasdaq Hurdle: What This Means for Its $1B+ Biotech Pipeline - Stock Titan
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway - MarketScreener
Hoth Therapeutics (HOTH) Reports Promising Preclinical Outcomes for Cancer Drug | HOTH Stock News - GuruFocus
Cancer Drug Breakthrough: Hoth's HT-KIT Achieves Perfect Safety Profile Ahead of Clinical Trials - Stock Titan
Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid By Investing.com - Investing.com India
Market Momentum Report: Hoth Therapeutics Inc (HOTH)’s Negative Close at 1.30 - DWinneX
Hoth Therapeutics Joins 20,000 Biotech Leaders at World's Largest Industry Convention - Stock Titan
Hoth Therapeutics (HOTH) Secures Patent for HT-KIT Platform in J - GuruFocus
Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World
Hoth Therapeutics secures Japanese patent for mast cell disease treatment By Investing.com - Investing.com South Africa
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - MarketScreener
Hoth Therapeutics secures Japanese patent for mast cell disease treatment - Investing.com
Hoth Therapeutics Secures 15-Year Japanese Patent Protection for Revolutionary Mast Cell Disease Platform - Stock Titan
Hoth Therapeutics (HOTH) Receives 'Buy' Rating from D. Boral Capital | HOTH Stock News - GuruFocus
Hoth Therapeutics plans expanded access program for cancer skin toxicity drug - Investing.com India
Hoth Therapeutics plans expanded access program for cancer skin toxicity drug By Investing.com - Investing.com South Africa
Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities - MarketScreener
Hoth Therapeutics Launches Expanded Access Initiative For HT-001 - MarketScreener
HOTH Seeks Expanded Access for HT-001 to Address Skin Toxicities | HOTH Stock News - GuruFocus
Hoth Expands Access to Cancer Skin Toxicity Treatment HT-001 in Phase 2a Success | HOTH Stock News - Stock Titan
Hoth Therapeutics advances with HT-001 oncology skin care treatment By Investing.com - Investing.com South Africa
Hoth Therapeutics advances with HT-001 oncology skin care treatment - Investing.com Australia
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities - PR Newswire
Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Large Increase in Short Interest - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Stock Rating Upgraded by Wall Street Zen - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Shares Up 0.7% – What’s Next? - Defense World
HT-KIT Shows Activity in Rare KIT-Driven Cancers, Preclinical Data Finds - Curetoday
Hoth Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Hoth Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Hoth Therapeutics Inc Azioni (HOTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):